Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Assets (2016 - 2026)

Syndax Pharmaceuticals (SNDX) has disclosed Current Assets for 12 consecutive years, with $471.2 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets fell 14.14% year-over-year to $471.2 million; the TTM value through Mar 2026 reached $471.2 million, down 14.14%, while the annual FY2025 figure was $528.1 million, 12.43% down from the prior year.
  • Current Assets hit $471.2 million in Q1 2026 for Syndax Pharmaceuticals, down from $528.1 million in the prior quarter.
  • Across five years, Current Assets topped out at $603.1 million in Q4 2024 and bottomed at $357.6 million in Q3 2022.
  • Average Current Assets over 5 years is $470.6 million, with a median of $453.9 million recorded in 2024.
  • Year-over-year, Current Assets surged 50.59% in 2022 and then decreased 14.14% in 2026.
  • Syndax Pharmaceuticals' Current Assets stood at $489.8 million in 2022, then grew by 18.6% to $580.9 million in 2023, then rose by 3.82% to $603.1 million in 2024, then decreased by 12.43% to $528.1 million in 2025, then decreased by 10.78% to $471.2 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $471.2 million, $528.1 million, and $529.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.